Thursday’s trading has closed, but TECH is being traded in the after-hours session.
After-Hours quote »| 86.55 Data as of 4:00pm ET |  +0.51 / +0.59%Today’s Change | 62.55 Today|||52-Week Range 89.99 | +26.65% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.2B |
Company Description
TECHNE Corp. is engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. Techne operates through two segments: Biotechnology and Hematology. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, including proteins such as cytokines and related reagents, to the biotechnology research community. The Hematology segment develops and manufactures hematology controls and calibrators for sale world-wide. The company was founded on July 17, 1981 and is headquartered in Minneapolis, MN.
Employees
Shareholders
| Mutual fund holders | 48.29% |
| Other institutional | 41.59% |
| Individual stakeholders | 4.83% |
Top Executives
| Charles R. Kummeth | President, Chief Executive Officer & Director |
| Gregory J. Melsen | Chief Financial Officer, Treasurer & VP |
| J. Fernando Bazan | Chief Technology Officer |
| Marcel Veronneau | Vice President-Clinical Controls |
| Kevin J. Reagan | Senior Vice President-Biotech |
.
